Recent research examined the use of apremilast in patients with psoriatic arthritis using the Clinical Disease Activity in Psoriatic Arthritis (cDAPSA) measurement. The findings suggest patients with moderate disease activity at baseline benefit most from the treatment…
ATLANTA—As many rheumatologists will recall, it was not too long ago that psoriatic arthritis was regarded somewhat like “rheumatoid arthritis with a rash,” with little attention paid to the ways in which the unique pathophysiology and manifestations of this entity make it distinct from other forms of inflammatory arthritis. At the 2019 ACR/ARP Annual Meeting…
Accurately classifying patients with psoriatic arthritis (PsA) can be difficult, especially patients with monoarticular/oligoarticular and polyarticular forms of PsA. A session at the 2019 European Congress of Rheumatology provided insight into the assessment and treatment of PsA subtypes…
Psoriatic arthritis came to be viewed as a distinct disease entity with specific clinical features, genetics and pathophysiology only gradually. One important historic development in this transition was a 1973 paper written by a pair of researchers out of Leeds, England: John M. Moll, BSc, DM, and Verna Wright, MD, FRCP.1 Here we discuss the…
Over the past few years, biosimilars and other new drugs have been introduced to treat rheumatic illnesses. Some of the conditions we treat have numerous drug options, others have few or only off-label options. This series, Rheumatology Drugs at a Glance, provides streamlined information on the administration of biologic, biosimilar and other medications used to…
Japan has approved risankizumab for treating plaque psoriasis, generalized pustular psoriasis, erythrodermic psoriasis and psoriatic arthritis in adults…
ACR guidelines include recommendations for the management of patients with particular conditions or diseases. Guidelines are developed using a systematic process and are based on available evidence and the clinical experience and expertise of rheumatologists and other interested stakeholders. In the January issue of Arthritis & Rheumatology, Arthritis Care & Research and the Journal of…
New research shows that patients with psoriatic arthritis (PsA) have a greater risk for developing type 2 diabetes than patients with psoriasis alone or the general population. Researchers also found that PsA and psoriasis patients have a similar rate of increased risk for cardiovascular disease…
In a four-year study, patients with active psoriatic arthritis (PsA) experienced sustained improvement in PsA signs and symptoms on secukinumab…